Ptc Therapeutics Stock Earnings Reports

PTC Therapeutics reported a record Q1 2026 driven by product revenue of $226M and total revenue of $273M. Management raised full‑year 2026 product revenue guidance to $750M–$850M (total revenue $1.08B–$1.18B), driven primarily by the Sephience global launch. Sephience Q1 revenue was $125M (U.S. $112M), with 1,244 commercial patients globally as of March 31 and a U.S. prescription start cadence ~140/month; management expects continued U.S. momentum and accelerated international rollout (commercial in up to 30 countries by year‑end). Real‑world signals include high persistence/refill rates, diet liberalization reports, and upcoming publications supporting Sephience’s dual mechanism; management reiterates a multi‑billion (>$2B) global opportunity. R&D highlights: positive 24‑month interim PIVOT‑HD long‑term extension results for votoplam (dose‑dependent clinical slowing vs natural history), increasing confidence in the partnered global Phase III INVEST‑HD; vatiquinone (Friedreich’s ataxia) will move forward with an FDA‑discussed open‑label study using a matched natural history control (FACOMS) targeting ~120 patients, 24‑month mFARS primary endpoint; Phase I of PTC612 (oral NLRP3 inhibitor) expected to start in Q2; progress on MSH3 splicing program for HD/DM1 and other inflammation/ferroptosis programs. Financial position remains strong with $1.89B cash and marketable securities as of March 31, 2026. Management emphasized disciplined BD flexibility to leverage the commercial rare disease engine.